Repeat surgery for recurrent low-grade gliomas should be standard of care

Low-grade gliomas (LGG) are a heterogeneous set of primary brain tumors that are diffuse and slow growing, and are composed of the following broad categories: diffuse astrocytoma, (IDH mutant), diffuse astrocytoma (IDH wild-type), diffuse astrocytoma (NOS), oligodendroglioma (IDH mutant and 1p/19q codeleted), oligodendroglioma (NOS), and oligoastrocytoma (NOS).[1] Approximately 2,000 to 3,000 cases of LGG are diagnosed annually in the US, with peak incidence between 35-44 years of age. While expectant management was previously the norm, current practice favors active intervention, including clinical consideration of surgery, radiotherapy (RT), chemotherapy, molecular characterization, and advanced imaging for diagnosis, prognosis, treatment and surveillance.
Source: Clinical Neurology and Neurosurgery - Category: Neurosurgery Authors: Source Type: research